Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Growth hormone and gonadotropin deficiency after brain injury: effects of hormone replacement
2010-020679-21Phase 2Terminated
- Sponsor
- Max Planck Institute of Psychiatry
- Start
- Nov 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of somatropin and testosterone undecanoate in growth hormone deficiency (GHD), hypogonadotropic hypogonadism (HH), hypopituitarism and 3 more (2 arms), sponsored by Max Planck Institute of Psychiatry. Primary endpoints: Change in SF-12 score, Change in QoL-AGHDA score and 4 more. Started Nov 2010; status: terminated.
02
Drugs
somatropintestosterone undecanoate
03
Conditions
growth hormone deficiency (GHD)hypogonadotropic hypogonadism (HH)hypopituitarismtraumatic brain injury (TBI)subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on 2010-020679-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020679-21.